Agios Pharmaceuticals | الأصول



Assets تغيير تاريخ
AbbVie USD 135.16B 8.26B 2024-12
Agios Pharmaceuticals USD 1.66B 128.6M 2024-12
Alnylam Pharmaceuticals USD 4.24B 34.94M 2024-12
Amgen USD 91.84B 956M 2024-12
Arrowhead Research USD 1.01B 126.11M 2024-12
Astellas Pharma JPY 3.45T 10.61B 2024-12
AstraZeneca USD 104.04B 887M 2024-12
Bayer EUR 110.85B 3.9B 2024-12
Biogen USD 28.05B 263.9M 2024-12
BioMarin Pharmaceutical USD 6.99B 137.74M 2024-12
Bristol-Myers Squibb USD 92.6B 1.07B 2024-12
Daiichi Sankyo JPY 3.44T 146.48B 2024-12
Eli Lilly USD 78.71B 3.11B 2024-12
Exelixis USD 2.95B 12.59M 2025-01
Gilead Sciences USD 59B 4.47B 2024-12
GlaxoSmithKline GBP 59.46B 1.41B 2024-12
Incyte USD 5.44B 431.89M 2024-12
Ionis Pharmaceuticals USD 3B 77.42M 2024-12
Merck USD 117.11B 426M 2024-12
Moderna USD 14.14B 1.66B 2024-12
Novartis USD 102.25B 1.28B 2024-12
Novartis USD 102.25B 1.28B 2024-12
Pfizer USD 213.4B 6.08B 2024-12
Regeneron Pharmaceuticals USD 37.76B 317.5M 2024-12
Roche Holding CHF 101.8B 6.02B 2024-12
Sarepta Therapeutics USD 3.96B 363.24M 2024-12
Vertex Pharmaceuticals USD 22.53B 293M 2024-12



Agios Pharmaceuticals الأصول - القيم الحالية، والبيانات التاريخية، والتنبؤات والإحصاءات والرسوم البيانية والتقويم الاقتصادي - Mar 2025.